Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer

NCT04374630 is registered in ClinicalTrials.gov with Laekna Limited as lead sponsor.

NCT NCT04374630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04374630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Randomized Active Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Lead sponsor
Laekna Limited
Phase
Phase 2
Overall status
Completed
Start date
June 9, 2020
Completion date
June 28, 2024
Enrollment
150 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

platinum-resistant ovarian cancer